Comparison of Dorzolamide/Timolol vs Brinzolamide/Brimonidine Fixed Combination Therapy in the Management of Primary Open-Angle Glaucoma. Issue 2 (March 2017)

• Record Type: Journal Article
• Authors: Kozobolis, Vassileios; Panos, Georgios D.; Konstantinidis, Aristeidis; Labiris, Georgios
• Is Part Of: European journal of ophthalmology. Volume 27:Issue 2(2017)
• Page Start: 160
• Page End: 163
• Publication Date: 2017-03
• Subjects: Brinzolamide/brimonidine -- Cosopt® -- Dorzolamide/timolol -- Glaucoma -- Simbrinza™ -- Intraocular pressure; Ophthalmology -- Periodicals; Eye -- Diseases -- Periodicals; 617.7005
• DOI: 10.5301/ejo.5000826
• Languages: English
• ISSNs: 1120-6721

Abstract

Purpose: To compare the efficiency of brinzolamide/brimonidine fixed combination vs the dorzolamide/timolol fixed combination. Methods: Forty-four eyes of 44 patients were divided in 2 groups treated either with dorzolamide/timolol twice a day (group A) or with brinzolamide/brimonidine twice a day (group B). Complete ophthalmic examination including Goldmann applanation tonometry was performed before treatment administration and 1, 4, 8, and 12 weeks afterwards. The intraocular pressure (IOP) was measured twice a day (morning at 9AM and afternoon at 4PM ). Results: At the end of the follow-up period (12 weeks), mean morning IOP reduction was 7.0 ± 2.8 mm Hg in group A and 8.4 ± 1.9 mm Hg in group B. A significant difference was found (p = 0.0343). In contrast, mean afternoon IOP reduction was 8.6 ± 2.7 mm Hg in group A and 7.9 ± 1.6 mm Hg in group B and no significant difference was found (p = 0.3413). No significant adverse effects were observed in either group. Conclusions: Brinzolamide/brimonidine seems to be an effective and safe alternative β-blocker free fixed combination, especially for patients with comorbidities, having its own antihypertensive profile.